ArticleMicrobial cell factories2026
Efficient vitamin A production in Lipomyces starkeyi through metabolic engineering of the β-carotene and retinoid pathways.
Article in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVitamin A, an essential micronutrient, is critical for vision, immune function, and cellular differentiation. Traditional vitamin A production methods, primarily based on chemical synthesis, pose significant environmental challenges. Microbial fermentation offers a sustainable alternative, but microbial production of vitamin A has yet to match chemical synthesis in terms of yield and cost-effectiveness. Oleaginous yeasts, such as Lipomyces starkeyi, which can synthesize high levels of acetyl-CoA and lipids, represent promising platforms for producing high-value lipophilic compounds, such as vitamin A.
resultsL. starkeyi was engineered for the first time to produce vitamin A by introducing key enzymes in the β-carotene and retinoid biosynthetic pathways. This approach included integrating genes encoding lycopene cyclase/phytoene synthase (McCarRP), phytoene desaturase (McCarB), and β-carotene 15,15'-dioxygenase (MbBlh). Further optimization of the mevalonate pathway enabled the production of over 600 mg/L vitamin A in a 3-L fed-batch fermentation. Fe
conclusionsThis study establishes L. starkeyi as a promising host for sustainable vitamin A production. Although significant improvements in yield were achieved, further optimization of pathway regulation and fermentation conditions is needed to reach economically competitive levels. These findings provide a foundation for developing L. starkeyi as a platform for large-scale production of vitamin A and other valuable terpenoids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.